Overview Fundamentals API Earnings EOD API Sample Code Pricing

SpringWorks Therapeutics Inc (SWTX NASDAQ) stock market data APIs

$39.17 0.26(0.7%) as of September 10, 2024
Price chart is built with Anychart

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

SpringWorks Therapeutics Inc Financial Data Overview

38.91
39.17
-
39.849
38.38
18-53.92
2 912 M
74 273 K
86 186 K
-0.54
0.788
Our easy-to-use no-coding solutions help you get the data effortlessly:

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'SWTX',
Type: 'Common Stock',
Name: 'SpringWorks Therapeutics Inc',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00Q011TW9',
ISIN: NULL,
CUSIP: NULL,
CIK: '813619',
EmployerIdNumber: '94-2551470',
FiscalYearEnd: 'December',
IPODate: '1987-06-05',
InternationalDomestic: 'Domestic',
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: 'Domestic',
IsDelisted: false,
}

SpringWorks Therapeutics Inc Fundamental Data is available in our Financial Data APIs

  • Net Revenue 86 186 K
  • EBITDA -318 708 992
  • Earnings Per Share -4.44
  • Income Statements
  • Balance Sheets
  • Cash flows
Get sample
of Fundamental API Data

Get SpringWorks Therapeutics Inc Earnings via APIs

  • Latest Release 2024-08-07
  • EPS/Forecast -1.11

Get SpringWorks Therapeutics Inc End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
Do you have any questions?
support@eodhistoricaldata.com